Loading
Extensive-stage SCLC after platinum-based chemotherapy
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Tarlatamab Bispecific T-cell engager (DLL3×CD3) | 1 mg day 1, 10 mg day 8 and day 15, then 10 mg every 2 weeks | IV | D1, 8 | inpatient monitoring 22-24 h after the first two doses for cytokine release syndrome |
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.